GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Next Science Ltd (ASX:NXS) » Definitions » Short-Term Debt

Next Science (ASX:NXS) Short-Term Debt : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Next Science Short-Term Debt?

Next Science's Short-Term Debt for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Next Science's quarterly Short-Term Debt increased from Dec. 2022 (A$0.00 Mil) to Jun. 2023 (A$0.40 Mil) but then declined from Jun. 2023 (A$0.40 Mil) to Dec. 2023 (A$0.00 Mil).


Next Science Short-Term Debt Historical Data

The historical data trend for Next Science's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Next Science Short-Term Debt Chart

Next Science Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Short-Term Debt
Get a 7-Day Free Trial - - - - -

Next Science Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.34 - 0.40 -

Next Science Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Next Science Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Next Science's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Next Science (ASX:NXS) Business Description

Traded in Other Exchanges
Address
821 Pacific Highway, Suite 1902, Level 19, Tower A, The Zenith Building, Chatswood, NSW, AUS, 2067
Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from the U.S. and Australia, of which prime revenue is derived from the U.S.

Next Science (ASX:NXS) Headlines

No Headlines